UK

[Funding alert] Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)

Oct 31, 2023 | By Startup Rise EU

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF). Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.
Kurt von Emster - Managing Partner & Head of Abingworth Life Sciences

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF). Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.

Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the US, UK, Europe, and Asia-Pacific, and create innovative therapeutics with potential to significantly improve human health.

Read also - UK-based Globacap Secures $21Million Series B Round Funding

Abingworth pioneered the clinical co-development (CCD) investment strategy in 2009, investing initially via its venture funds and then through its first dedicated fund, Abingworth Clinical Co-Development Fund (ACCD 1), which launched in 2016 raising $109 million.

RECOMMENDED FOR YOU

recomd
Funding
Eleos funding news – Insurtech Company Eleos has Secures €3.75 Million in a Seed Funding
Startup Rise EU
May 8, 2024
recomd
Funding
Carv funding news – Amsterdam-based Carv Secures $10Million in Seed Funding
Startup Rise EU
Jun 4, 2024
recomd
Funding
Polestar Capital’s Circular debt fund funding news – Netherlands-based Polestar Capital’s Circular debt fund (PCDF) Raises €43Million in Debt Fund
Startup Rise EU
Jul 4, 2024

Bali Muralidhar, Managing Partner, Chief Investment Officer & COO said,“Our clinical co-development approach has proved to be a great success as an alternative investment strategy since we pioneered the concept more than a decade ago, in terms of gaining new product approvals, getting new medicines to patients, and generating returns for investors. Our CCD program creates bespoke investment and operational solutions that enable resource-constrained pharma companies to pursue additional clinical projects and biotech companies to avoid near-term equity dilution,” .

Kurt von Emster, Managing Partner & Head of Abingworth Life Sciences said, “We are delighted to announce this new Clinical Co-Development Co-Investment Fund that, combined with Abingworth Bioventures 8 and ACCD 2, brings new funds closed by Abingworth to over $1.4 billion since 2020,”.

About Abingworth

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 185 life science companies, leading to 49 M&As and 75 IPOs.

Read also -  Amsterdam-based Climate Tech Startup Overstory Secures $14M Series A Round Funding

Recommended Stories for You

story
Funding

[Funding alert] Germany-based Langdock Secures $3Million in Seed Funding

Startup Rise EU Apr 20, 2024

story
Funding

[Funding alert] London-based Klu Secures €1.6 Million in Pre-Seed Funding

Startup Rise EU Oct 24, 2023

story
Funding

[Funding alert] Glasgow-based Munro Vehicles Secures £1 Million in Funding

Startup Rise EU Dec 19, 2023

story
Funding

[Funding alert] Paris-based Kraaft Secures €3.2 million in Funding

Startup Rise EU Oct 4, 2023

story
Funding

Bcas funding news – Madrid-based Bcas Secures €17 Million in Funding

Startup Rise EU Jun 3, 2024

story
Finland

[Funding alert] Finnish-based Biochemical Company Montinutra Secures €2 million in Pre-A Funding

Startup Rise EU Oct 26, 2023